Positron emission tomography combined with computed tomography (PET/CT) enables assessment of not only anatomical and structural but also metabolic changes in tumor mass. F-fluoroethyl tyrosine (F-FET) PET/CT is based on evaluation of transport of F-labeled tyrosine in tissues. We present a clinical case of a patient with a newly diagnosed brain tumor, demonstrating the capabilities ofF-FET PET/CT in assessing the reliable volume and degree of tumor anaplasia, which is important when choosing the treatment approach for a patient.
BackgroundThe purpose of the study to evaluate possibilities of CT-perfusion and PET methods with 18F–FDG and 18F–fluorocholine in the complex diagnosis of hepatocellular carcinoma. The study included the results of PET/CT with 18F–FDG, 18F–FCh and CT-perfusion of the liver in 18 patients with histologically confirmed diagnosis of hepatocellular carcinoma (HCC). Depending on the degree of tumor differentiation, all patients were divided into 3 groups - patients with highly differentiated (6 patients), moderately differentiated (4 patients), and low-differentiated HCC (8 patients).ResultsAverage values of maxSUV in the group of patients with highly differentiated HCC in PET/CT with 18F–FDG and 18F- fluorocholine in a solid component of tumor reached 3.51 and 18.24, respectively; in patients with moderately differentiated HCC - 3.91 and 12.32, respectively; in patients with low-differentiated HCC - 9.58 and 9.70, respectively. Average values of CT perfusion imaging in a solid component of the tumor in the group of patients with highly differentiated HCC were the following: BF - 55,33 ml/100 ml/min, BV - 13,71 ml/100 ml, ALP - 52,41 ml/100 ml/min, PVP - 10.81 ml/100 ml/min (p ≤ 0,05), in the group of patients with moderately differentiated HCC: BF - 52,78 ml/100 m /min, BV - 12,23 ml/100 ml, ALP - 47,26 ml/100 ml/min, PVP - 9,10 ml/100 ml/min (p ≤ 0.05), in the solid component of low-differentiated HCC: BF - 46,96 ml/100 ml/min, BV - 9,49 ml/100 ml, ALP - 40.54 ml/100 ml/min, PVP - 7,66 ml/100 ml/min (p ≤ 0,05).ConclusionsThe diagnostic capabilities of the complex of PET/CT techniques with 18F–FDG and 18F–FCh and CT perfusion in a single-scan mode for hepatocellular carcinoma were evaluated for the first time. The obtained data allow to assume that the integrated use of PET with 18F–FDG and 18F–FCh and CT perfusion in a single scan improves the differential diagnostic possibilities of PET/CT diagnostics, which can find application in planning and prognosis of the disease. Due to the small number of patients further study of the problem is required.
Aim: to explore the opportunities of application of diffusionkurtosis imaging (DKI) for assessment and estimation of diffusion scalar metrics in different locations of peritumoral edema for extra- and intracerebral tumors and in contralateral normal tissue.Materials and methods. 38 patients with supratentorial brain tumors were investigated: 24 (63%) patients with primarily revealed glioblastomas (GB) and 14 (37%) patients with solitary cancer brain metastasis (MTS). MRI was performed on 3.0 T MR-scanner (Signa HDxt, General Electric, USA) with the standard protocols for brain tumor and additional protocol for DKI. The standard protocol for brain tumor included: T1-, T2-weighted images, T2-FLAIR, DWI, T1 with contrast enhancement. Diffusion kurtosis MRI based on SE EPI with TR = 10000 ms, TE = 102 ms, FOV = 240 mm, isotropic voxel size 3 × 3 × 3 mm3, 60 noncoplanar diffusion directions. We used three b-values: 0, 1000 and 2500 s/mm2. Аcquisition time was 22 min. Total acquisition time was near 40 min. This study was approved by Ethical committee of Burdenko National Scientific and Practical Center for Neurosurgery. Parametric maps were constructed for the following diffusion coefficients: mean (MK), transverse / radial (RK), longitudinal / axial (AK) kurtozis; medium (MD), transverse / radial (RD) and longitudinal / axial (AD) diffusion; fractional anisotropy (FA) and a bi-exponential diffusion model coefficients: axonal water fractions (AWF), axial (AxEAD) and radial (RadEAD) extra-axonal water diffusion and the water molecules trajectory tortuosity index (TORT). Normative quantitative indicators were obtained for the six regions of the peritumoral zone as they moved away from the tumor (region 2) to the edema periphery (regions 4–5), as well as in the normal brain on the contralateral hemisphere (C/L) (zone 7). A comparative analysis of these indicators was conducted for cases with GB and MTS. DKI scalar metrics were estimated using Explore DTI (http://www.exploredti.com/).Results. Anatomic MRI (T1 without/with contrast enhancement) for all cases with GB and MTS visualized a contrast enhancement tumor. The peritumoral edema, spreading mainly over the brain white matter, was well visualized on T2-FLAIR. Diffusion kurtosis coefficients decreased in the near peritumoral edema (regions 2–3) and a gradually increased to the edema periphery (regions 5–6). In Region 2, MK in both GB and MTS groups were MKGB(2) = 0.637 ± 0.140 and MKMTS(2) = 0.550 ± 0.046; RK in this region were RKGB(2) = 0.690 ± 0.154 and RKMTS (2) = 0.584 ± 0.051. Differences both MK and RK coefficients in patients with GB and MTS of region 2 were significant (p < 0.001). There were no differences in AK values for GB and MTS in region 2 (p > 0.05), but in regions 3 and 4 differences were observed (p < 0.01). The minimum value of AK in the central edema (regions 3–4) was AKMTS(3–4) = 0.433 ± 0.063 in patients with MTS. The values of MK and RK on the contralateral side in patients with MTS were significantly higher than in the GB group (p < 0.02); MKC/LMTC = 0.954 ± 0.140, RKC/LMTC = 1.257 ± 0.308 and MKC/LGB = 0.829 ± 0.146, RKc/LGB = 0.989 ± 0.282. There was no significant difference for contralateral AK between the groups.Conclusions. We found that DKI scalar metrics are the sensitive tumor biomarkers. It allows us to perform a robust differentiation between the infiltrating GB tumor and purely vasogenic edema of МТS. The obtained results will allow further differential diagnosis of extra- and intracerebral tumors and can be used to plan surgical / radiosurgical treatment for brain tumors.
The study objective is to evaluate the diagnostic capabilities of complex method based on the use of 18 F-fluoroethyltyrozine positron emission tomography (PET) combined with computed tomography (CT) and CT perfusion in the differential diagnosis of glial brain tumors.Materials and methods. One hundred and two patients with glial brain tumors were included in the study. Depending on the degree of malignancy patients were divided into 2 groups: group 1–38 (37.26 %) patients with grade I–II tumors; group 2–64 (62.74 %) patients with grade III–IV tumors. Perfusion CT was performed in 20 (52.6 %) patients from the group with grade I–II tumors and 37 (57.8 %) patients from the group with grade III–IV gliomas. The sensitivity and specificity of such indicators as the maximum standardized uptake value (maxSUV) and the tumor to brain ratio (TBR), in combination with CT perfusion indicators (cerebral blood flow (CBF), cerebral blood volume (CBV), vascular permeability (FED) were studied.Results. The highest diagnostic accuracy was demonstrated by the following parameters: maxSUV 1 (sensitivity and specificity 81 and 82 %, threshold value 2.51, AUC 0.87); TBR 1 (sensitivity and specificity 90.6 and 81.6 %, threshold value 2.07, AUC 0.89). The comprehensive evaluation of CT perfusion and 18 F-fluoroethyltyrozine PET / CT parameters: sensitivity and specificity of TBR 1 + CBF – 97.1 and 94.4 %, respectively; TBR 1 + CBV – 96.6 and 94.4 %, respectively; TBR 1 + FED – 94.6 and 92.3 %, respectively.Conclusion. According to results of obtained analysis, an increase in diagnostic accuracy was revealed for all studied parameters with complex use of two methods – 18 F-fluoroethyltyrozine PET / CT and CT perfusion, in differential diagnosis of glial brain tumors.
Objective: demonstration of possibilities of18F-prostate specific membrane antigen-1007 (18F-PSMA-1007) positron emission tomography/computed tomography (PET/CT) for diagnostic prostate cancer recurrence.The article presents clinical observation of the patient with prostate cancer biochemical recurrence after the multiple treatment.18F-PSMA-1007 PET/CT demonstrates high sensitivity in prostate cancer recurrence diagnostic, in particular with low prostatic specific antigen level.
Primary hyperparathyroidism (PHPT) is caused by parathyroid malignant neoplasm in 1% of cases. The risk of the latter is higher in patients with symptomatic PHPT. The prognosis in this group of patients depends on the extent of the process and primary surgical intervention. In these cases, the differential diagnosis between secondary foci in the bones associated with parathyroid cancer and hyperparathyroid osteodystrophy is a challenging problem. This article describes two cases of severe PHPT accompanied by hyperparathyroid osteodystrophy suspected for metastatic parathyroid cancer. Positron emission tomography in combination with computed tomography (PET/CT) with 18F-fluorodeoxyglucose (18F-FDG) and/or 18F-fluorocholine was included in the examination algorithm. In both cases, pronounced bone changes similar to parathyroid metastases were observed. Accumulation of 18F-fluorocholine was also observed only in altered parathyroid gland. Histological examination of postoperative material verified benign parathyroid tumors, and characteristic lesions of bone tissue were regarded as areas of osteodystrophy. Therefore, accumulation of 18F-fluorocholine at the areas of bone destruction does not enable differentiation between hyperparathyroid osteodystrophy and metastatic lesions; further research is required to assess sensitivity and specificity of the method with respect to topical diagnosis of altered parathyroid gland.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.